Effect of Topical Imiquimod on Lentigo Maligna

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Status Completed

Clinical Trial Summary

The purpose of this study is to determine if topical imiquimod is effective in the pathological complete regression of lentigo maligna.

n/a

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

NCT number	NCT01161888
Study type	Interventional
Source	University Hospital Birmingham NHS Foundation Trust
Contact
Status	Completed
Phase	Phase 4
Start date	June 2010
Completion date	March 2012

See also
Status	Clinical Trial	Phase
Completed	`NCT06046144` - Comparison of 3 in Vivo Microscopic Imaging Techniques for the Diagnosis of Pigmented Tumors
Completed	`NCT00707174` - Combination Therapy With Imiquimod Cream 5% and Tazarotene Cream 0.1% for the Treatment of Lentigo Maligna	N/A
Completed	`NCT03508297` - Reflectance Confocal Microscopy to Diagnose MM & LM
Withdrawn	`NCT02306512` - Mohs and Immunofluorescence for Malignant Melanoma In Situ	N/A
Completed	`NCT02723721` - Prospective Study of Ingenol Mebutate for Non-invasive Lentigo Melanoma of the Face	Phase 2
Terminated	`NCT04688749` - Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
Active, not recruiting	`NCT01088737` - Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna	Phase 2/Phase 3
Completed	`NCT02685592` - Photodynamic Therapy for Lentigo Maligna Using 5-aminolevulinic Acid Nanoemulsion as a Light Sensitizing Cream	Phase 4
Active, not recruiting	`NCT02394132` - Radiotherapy or Imiquimod in Complex Lentigo Maligna	Phase 3
Completed	`NCT00785369` - In Vivo Confocal Microscopy for Pigmented Lesion Diagnosis	N/A
Recruiting	`NCT06014619` - Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs